New insights on poly(vinyl acetate)-based coated floating tablets: characterisation of hydration and CO2 generation by benchtop MRI and its relation to drug release and floating strength.

The purpose of this study was to investigate the mechanism of floating and drug release behaviour of poly(vinyl acetate)-based floating tablets with membrane controlled drug delivery. Propranolol HCl containing tablets with Kollidon SR as an excipient for direct compression and different Kollicoat SR 30 D/Kollicoat IR coats varying from 10 to 20mg polymer/cm2 were investigated regarding drug release in 0.1N HCl. Furthermore, the onset of floating, the floating duration and the floating strength of the device were determined. In addition, benchtop MRI studies of selected samples were performed. Coated tablets with 10mg polymer/cm2 SR/IR, 8.5:1.5 coat exhibited the shortest lag times prior to drug release and floating onset, the fastest increase in and highest maximum values of floating strength. The drug release was delayed efficiently within a time interval of 24 h by showing linear drug release characteristics. Poly(vinyl acetate) proved to be an appropriate excipient to ensure safe and reliable drug release. Floating strength measurements offered the possibility to quantify the floating ability of the developed systems and thus to compare different formulations more efficiently. Benchtop MRI studies allowed a deeper insight into drug release and floating mechanisms noninvasively and continuously.

[1]  Sanford Bolton,et al.  A Floating Controlled-Release Drug Delivery System: In Vitro-in Vivo Evaluation , 1993, Pharmaceutical Research.

[2]  J. Timmermans,et al.  The Bilayer Floating Capsule: A Stomach-Directed Drug Delivery System for Misoprostol , 1992, Pharmaceutical Research.

[3]  Xiao Xia Zhu,et al.  NMR imaging of high-amylose starch tablets. 2. Effect of tablet size. , 2002, Biomacromolecules.

[4]  Gan-Lin Chen,et al.  In vitro performance of floating sustained-release capsule of verapamil. , 1998, Drug development and industrial pharmacy.

[5]  N. M. Sanghavi,et al.  Novel drug delivery system for captopril , 1992 .

[6]  F. Syrowatka,et al.  Monitoring of dissolution induced changes in film coat composition by 1H NMR spectroscopy and SEM. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[7]  H. Metz,et al.  Characterization of poly(vinyl acetate) based floating matrix tablets. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Xiao Xia Zhu,et al.  Imaging of high-amylose starch tablets. 3. Initial diffusion and temperature effects. , 2005, Biomacromolecules.

[9]  C. Rhodes,et al.  Development of a Novel Controlled-Release System for Gastric Retention , 1997, Pharmaceutical Research.

[10]  W. Sawicki,et al.  Compressibility of floating pellets with verapamil hydrochloride coated with dispersion Kollicoat SR 30 D. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  U. Fuhr,et al.  Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule. , 1990, British journal of clinical pharmacology.

[12]  A. Sakr,et al.  Evaluation of the new polyvinylacetate/ povidone excipient for matrix sustained release dosage forms , 2001 .

[13]  Hendrik Metz,et al.  Mechanistic analysis of drug release from tablets with membrane controlled drug delivery. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  A. Hoffman,et al.  Furosemide Pharmacokinetics and Pharmacodynamics following Gastroretentive Dosage Form Administration to Healthy Volunteers , 2003, Journal of clinical pharmacology.

[15]  S. Al-suwayeh,et al.  In vitro and in vivo evaluation of floating controlled release dosage forms of verapamil hydrochloride , 2004 .

[16]  A. Hoffman,et al.  Expandable gastroretentive dosage forms. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Juergen Siepmann,et al.  Gastroretentive drug delivery systems , 2006, Expert opinion on drug delivery.

[18]  J. Timmermans,et al.  How well do floating dosage forms float , 1990 .

[19]  E. Doelker,et al.  Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery , 1996 .

[20]  Xiao Xia Zhu,et al.  NMR imaging of high-amylose starch tablets. 1. Swelling and water uptake. , 2002, Biomacromolecules.

[21]  J. Robinson,et al.  Bioadhesive-based dosage forms: the next generation. , 2000, Journal of pharmaceutical sciences.

[22]  Nicholas A Peppas,et al.  Floating hot-melt extruded tablets for gastroretentive controlled drug release system. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[23]  J. Fell,et al.  Amoxycillin release from a floating dosage form based on alginates. , 2000, International journal of pharmaceutics.

[24]  C. Beglinger,et al.  The absorption site of cyclosporin in the human gastrointestinal tract. , 1992, British journal of clinical pharmacology.